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Abstract 
Aims 
Type 2 diabetes is a major health problem placing increasing demands on healthcare 
systems. Our objective was to estimate healthcare resource use and related financial 
costs following treatment with exenatide-based regimens prescribed as once-weekly 
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(EQW) or twice-daily (EBID) formulations, compared with regimens based on basal 
insulin (BI). 
Materials and methods 
This retrospective cohort study used data from the UK Clinical Practice Research 
Datalink (CPRD) linked to Hospital Episode Statistics (HES). Patients with type 2 
diabetes prescribed exenatide or BI between 2009 to 2014 as their first recorded 
exposure to injectable therapy were selected. Costs were attributed to primary care 
contacts, diabetes-related prescriptions and inpatient admissions using standard UK 
healthcare costing methods (2014 prices). Frequency and costs were compared 
between cohorts before and after matching by propensity score using Poisson 
regression.  
Results 
8,723, 218 and 2,180 patients prescribed BI, EQW and EBID were identified. 188 and 
1,486 patients prescribed EQW and EBID, respectively, were matched 1:1 to BI 
patients by propensity score.  Among unmatched cohorts, total crude mean costs 
per patient-year were £2,765 for EQW,  £2,549 for EBID and £4,080 for BI. Compared 
with BI, the adjusted annual cost ratio (aACR) was 0.92 (95% CI 0.91–0.92) for EQW 
and 0.82 (0.82–0.82) for EBID. Corresponding costs for the propensity-matched 
subgroups were £2,646 versus £3,283 (aACR 0.80, 0.80–0.81) for EQW versus BI and 
£2,532 versus £3,070 (0.84, 0.84–0.84) for EBID versus BI.  
Conclusion 
Overall, treatment with EQW and EBID was associated with reduced healthcare 
resource use and costs compared with BI.   
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Introduction 
Type 2 diabetes (T2DM) is a major health problem and places increasing demands on 
healthcare systems. The direct and indirect cost of type 2 diabetes in the UK in 
2010/2011 has been estimated to be £21.8 billion.1 Normoglycaemia remains a 
primary aim in the management of type 2 diabetes. Although, in the early stages, the 
condition can be managed using diet and lifestyle adjustments alone, glucose-
lowering therapies are usually required for the management of hyperglycaemia. As 
glucose control deteriorates, intensification using combination therapy and 
eventually insulin injection is recommended. However, the achievement of adequate 
glucose control often needs to be weighed against the risk of inducing side effects 
such as hypoglycaemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor 
agonists have been recommended as an alternative to insulin.2 Exenatide, the first 
GLP-1 receptor agonist to reach the market has been reported to be associated with 
similar or greater reductions in glycated haemoglobin (HbA1c) when compared with 
long-acting insulin analogues
3–10
 and is associated with weight reductions.
3
 In 
addition to the immediate-release formulation to be used twice a day, exenatide is 
also available as an extended-release formulation, thereby offering the advantage of 
a simpler dosing regimen. 
In the CHOICE (CHanges to Treatment and Outcomes in Patients With Type 2 
Diabetes Initiating InjeCtablE Therapy) observational study based in six European 
countries, total healthcare costs were higher over a 24-month period in those 
prescribed twice-daily exenatide when compared with those prescribed insulin 
(€3,998 versus €3,267).
11
 However, following the exclusion of the cost attributed to 
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insulin or twice-daily exenatide, the cost of other healthcare resource utilization was 
lower for exenatide (€1792 versus €2466).
11
  
In addition to clinical factors, cost can be an important consideration when selecting 
the most appropriate glucose-lowering therapy to initiate in patients with type 2 
diabetes.2 In this retrospective, observational cohort study, we aim to estimate, 
using UK primary and secondary care data, NHS resource use and related costs in 
patients who are prescribed regimens that include exenatide in its once-weekly 
(EQW) or twice-daily formulation (EBID), compared with regimens including basal 
insulin (BI). To our knowledge, this is the first study to compare the use and cost of 
NHS healthcare resources in patients treated with exenatide and insulin.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
Materials and methods 
Data sources 
Retrospective data were extracted from the United Kingdom Clinical Practice 
Research Datalink (CPRD). CPRD is a proprietary healthcare data resource containing 
clinically rich, anonymized data on 14 million research-quality patients registered at 
689 UK primary care practices, of which 4.9 million patients are actively registered 
(representing approximately 7% of the UK population). These data are collected in a 
non-interventional manner and include patient demographics, consultations, 
medical history, test results and prescriptions. Patients registered in CPRD are 
broadly representative of the UK population in terms of age and sex.12 The 
geographical distribution of patients and practices in CPRD has been described 
previously. Briefly, the percentage of acceptable patients registered in CPRD by 
region varies between 3.9% from Yorkshire and the Humber to 11.1% from the North 
West of England.
12
 Patient-level data from a proportion of consenting English CPRD 
practices are linked to Hospital Episode Statistics (HES) inpatient data. Data were 
available from 1987 until June 2015. Approval for this study was granted by the 
CPRD Independent Scientific Advisory Committee (reference number 15_178R). 
 
Patients 
Patients with type 2 diabetes and naïve to injectable therapies were selected if they 
received their first recorded prescription for EQW, EBID or BI  between 1 January 
2009 and 31 December 2014. Patients were classified as having type 2 diabetes if 
they met at least one of the following criteria: more than one diagnosis for type 2 
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diabetes, prescriptions for more than one class of glucose-lowering therapy, or at 
least one diagnosis of type 2 diabetes plus at least one prescription for an oral 
glucose-lowering therapy. Analysis was restricted to those English practices that 
were part of the CPRD linkage scheme. The percentage of CPRD practices linked to 
HES records varied from 83.6% in the South West to 52.0% in the East Midlands. This 
allowed access to hospital data recorded in HES. Patients were excluded if they had 
secondary diabetes. 
The index date was defined as the date of the first recorded prescription for 
exenatide or BI. For the main analysis, no minimum wash-in period prior to index 
date was required. The censor date was defined as the earliest of: end of therapy 
(defined as last prescription +90 days), date of death, end of CPRD follow-up and the 
end of HES follow-up (31 March 2015). End of CPRD follow-up was defined as the 
earlier of: the patient’s transfer out date and the practice’s last data collection date. 
Continuous periods of therapy were identified as such if there were no more than 
112 days between prescriptions for the same drug, with this interval being based on 
the 95th percentile of the maximum number of days prescribed for each patient. 
 
Primary care contacts 
Primary care consultations were classified by consultation type (e.g. surgery 
appointment, clinic, home visit, telephone consultation) and staff type (e.g. general 
practitioner (GP), practice nurse, district nurse) and then assigned a unit cost as 
listed in the Unit Cost of Health and Social Care 2015 from the Personal Social 
Services Research Unit (PSSRU).13 For some staff roles, the cost per consultation was 
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not published in the Unit Cost of Health and Social Care. Therefore, mean length of 
consultation was obtained from the UK GP workload survey
14
 and used to calculate 
the average cost per consultation from the unit cost per hour. Where a member of 
staff in an administrative role recorded the consultation, it was assumed that the 
consultation itself was carried out by a GP. 
 
Prescriptions 
Prescriptions for glucose-lowering therapies (including glucose-lowering therapies 
other than BI or exenatide prescribed concomitantly), injection equipment (needles 
and syringes), equipment used for the self-monitoring of blood glucose (strips and 
lancets), drugs used for the treatment of obesity, antihypertensives, antiplatelets 
and lipid-lowering therapies were identified in CPRD. Each prescription was matched 
to the corresponding product listed in the Prescription Cost Analysis (PCA) report for 
201415 and attributed a net ingredient cost (NIC) per quantity. The NIC refers to the 
cost of the drug before discounts and does not include any dispensing costs or 
fees.
15
 For those products that were discontinued before 2014 and therefore not 
included in the 2014 PCA, the NIC per quantity listed in the most recent prior version 
of the PCA was used and the cost inflated to 2014 prices using the Gross Domestic 
Product Deflator from Her Majesty’s Treasury.
16
  
The quantity of medication entered in each of the relevant prescriptions was 
determined and its unit converted, if necessary, to the Standard Quantity Unit used 
for the corresponding product in the PCA. This quantity was then multiplied by the 
NIC per quantity in order to determine the cost of each prescription.  
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Secondary care resource use 
Data from inpatient admissions recorded in HES were processed into Healthcare 
Resource Groups (HRGs) using HRG-4 grouper. The allocated Healthcare Resource 
Groups (HRGs) were linked to the 2013–14 National Tariff,17 adjusting for the nature 
of the admission (elective versus emergency) and excess length of stay.  
 
Statistical analysis 
Continuous baseline characteristics were compared using the independent t-test or 
Mann–Whitney U test depending on their distribution. Categorical variables were 
compared using the chi-squared test. Frequency and cost of primary care contacts 
and inpatient admissions were compared using adjusted annual cost ratios (aACR). 
These were estimated from a Poisson regression model that adjusted for the 
following baseline characteristics: age, gender, glycated haemoglobin (HbA1c), body 
mass index (BMI), Charlson comorbidity index,
18
 the number of GP contacts in the 
year prior to index date, smoking status and the duration of diagnosed diabetes.  
 
Sensitivity analysis 
As a sensitivity analysis, patients were required to have been registered at their GP 
practice for at least 90 days before the index date in order to identify incident 
therapies. 
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Additional sensitivity analyses were performed based on cohorts matched by 
propensity score. The following baseline criteria were used to generate the 
propensity score: age at index date, sex, BMI, duration of diagnosed diabetes, index 
year, HbA1c, smoking status, serum creatinine, systolic blood pressure (BP), total 
cholesterol and Charlson index. For BMI, HbA1c, serum creatinine, systolic blood 
pressure, and total cholesterol the nearest recorded measurement to the index date 
was selected providing this was no more than 365 days before or 30 days after the 
index date. The search was conducted in the following order: -30, +30 and -365 days. 
For smoking, the nearest recorded status prior to the index date was selected. 
Where no status was recorded prior to the index date, the nearest recorded status 
after the index date was used. The duration of diabetes was calculated as the time 
between the diabetes presentation date and the index date. The Charlson 
comorbidity index was calculated by identifying relevant medical diagnoses recorded 
prior to the index date. Where the patient history prior to index date was shorter 
than 365 days, then the shorter period prior to index date was searched for the 
relevant baseline criteria. The caliper was set at 0.1. Patients with missing values for 
any of the characteristics used to generate the propensity score were excluded from 
the matching process. Propensity score matching produced four treatment cohorts: 
patients prescribed EQW and the corresponding matched BI cohort and patients 
prescribed EBID and the corresponding matched BI cohort.  
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Results 
8,723 patients prescribed BI, 218 patient prescribed EQW and 2,180 patients 
prescribed EBID were identified. Total exposure time was 8,715 years. Mean follow-
up was as follows: 0.75 years for BI, 0.85 years for EQW and 0.93 years for EBID. 
 
Baseline characteristics 
Patients prescribed BI were older than those prescribed EQW (mean age 64.8 versus 
55.7 years, p <0.001) and EBID (64.8 versus 56.6 years, p <0.001), with a longer 
duration of diagnosed diabetes (median 9.1 years for BI; 8.0 years, p<0.005, for 
EQW; 7.4 years, p<0.001, for EBID). HbA1c at baseline was higher for patients 
prescribed BI in comparison with those prescribed EQW (9.7% versus 9.3%, p<0.001) 
and EBID (9.7% versus 9.2%, p<0.001). More patients prescribed BI had a history of 
major adverse cardiac events and cancer when compared with those prescribed 
EQW (19% versus 9%, p<0.001, for major adverse cardiac events and 14% versus 6%, 
p=0.001, for cancer) and EBID (19% versus 9%, p<0.001, for major adverse cardiac 
events and 14% versus 6%, p<0.001, for cancer). Patients prescribed BI also had a 
higher Charlson index (3.0 versus 2.0, p<0.001, for BI versus EQW and 3.0 versus 2.0, 
p <0.001, for BI versus EBID). Prior antiplatelet therapy was also more common in 
patients prescribed BI than in those prescribed EQW (44% versus 36%, p=0.020). 
However, patients prescribed BI had a lower BMI when compared with those 
prescribed EQW (30.0 versus 38.0 kg/m
2
, p<0.001) and EBID (30.0 versus 38.6 kg/m
2
, 
p<0.001). Fewer patients prescribed BI had received prescriptions for lipid-lowering 
therapy when compared with EQW (72% versus 78%, p=0.037) and EBID (72% versus 
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79%, p<0.001), and fewer patients prescribed BI had received prescriptions for 
antihypertensive therapy when compared with EBID (72% versus 85%, p<0.001).  
5,987 patients prescribed BI, 193 patients prescribed EQW and 1,913 patients 
prescribed EBID had no missing data for any of the characteristics used to generate 
the propensity score. 188 patients prescribed BI were successfully matched to 188 
patients prescribed EQW, and 1,486 patients prescribed BI were matched to 1,486 
patients prescribed EBID. Following propensity-score matching, more patients 
prescribed EQW had previously been prescribed lipid-lowering therapy compared 
with those prescribed BI (79% versus 69%, p=0.019). Duration of diagnosed diabetes 
was longer for those prescribed EBID than in those receiving BI (median 7.8 versus 
7.4 years, p=0.018), and diastolic blood pressure (78.8 versus 78.1 mmHg, p=0.039) 
and BMI (36.9 versus 36.1 kg/m2, p<0.001) were also higher in those prescribed 
EBID. No other significant differences in the baseline characteristics between 
matched cohorts were observed. 
A sensitivity analysis was carried out using those patients with a minimum wash-in of 
90 days between the patient’s current registration date with their GP practice and 
the study index date. Baseline characteristics of these patients are detailed in 
Supplementary Table 1. 
 
Healthcare Resource Use 
Overall, the cost of glucose-lowering therapies was higher in patients prescribed 
EQW than in those prescribed BI (£914 versus £507 per patient year (ppy), aACR 
1.55, 95% CI 1.55–1.56, Table 2a). Following propensity-score matching this 
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difference remained (£926 versus £556 ppy, aACR 1.69, 1.68–1.71). However, lower 
costs were observed in those prescribed EQW for primary care contacts (£976 versus 
£1,178 ppy, aACR 0.95, 0.94–0.95), hospital admissions (£760 versus £2,096 ppy, 
aACR 0.65, 0.65–0.66) and total costs (£2,765 versus £4,080 ppy, aACR 0.92, 0.91–
0.92). The corresponding costs for patients prescribed EQW and BI in the propensity-
matched subgroup were £944 versus £1,059 ppy (aACR 0.89, 0.89–0.90) for primary 
care contacts, £654 versus £1,349 ppy (0.48, 0.47–0.48) for hospital admissions and 
£2,646 versus £3,283 ppy (0.80, 0.80–0.81) total costs, respectively.  
When compared with those prescribed BI, lower total costs were observed in those 
prescribed EBID in the mains analysis (£2,549 versus £4,080 ppy, aACR 0.82, 0.82–
0.82) and following propensity-score matching (£2,532 versus £3,070 ppy, 0.84, 
0.84–0.84). A detailed breakdown of resource use and cost for those prescribed BI 
and EBID is provided in Table 2b. 
In the sensitivity analysis selecting only those patients with a wash-in of ≥90 days 
between current registration date and index date, patients prescribed EQW had 
lower overall costs compared with those allocated to the  BI cohort overall (£2,809 
versus £3,857 ppy, aACR 0.99, 95% CI 0.99–0.99) and in the subgroup matched by 
propensity score (£2,782 versus £3,616, 0.92, 0.91–0.92, Supplementary Table 2a). 
Patients prescribed EBID had lower total costs when compared with those treated 
with BI in the overall analysis (£2,534 versus £3,857 ppy, aACR 0.86, 95% CI 0.86–
0.86) and following propensity score matching (£2,543 versus £3,032, 0.82, 0.82–
0.82, Supplementary Table 2b).  
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Discussion 
Compared with patients treated with BI, patients treated with exenatide in its once-
weekly (EQW) and twice-daily (EBID) formulations had significantly lower rates of 
primary care contacts and inpatient admissions and, consequently, lower total 
financial costs in spite of exenatide’s higher pharmacy cost. Lower total costs for 
patients treated with EQW or EBID were also observed in the propensity-score-
matched analysis. However, total costs were lower in the subgroup of BI patients 
matched by propensity score than in the original BI cohort. This is likely to be related 
to the decrease in mean age of patients prescribed BI following propensity-score 
matching where age is related to increased disease severity, increased morbidity and 
patient frailty.  
In several studies, exenatide has been reported to have numerous clinical benefits 
when compared with insulin. In a meta-analysis by Wang and colleagues, GLP-1 
receptor agonists were associated with greater reductions in HbA1c and weight 
(which may help to mitigate cardiovascular risk) in comparison with insulin.
19
 
Furthermore, in randomized trials, EQW has been reported to provide improved 
glycaemic control versus EBID.
20,21
 In a retrospective study, exenatide was associated 
with a reduced cardiovascular risk versus insulin.
22
  
It is important for patented products such as exenatide to demonstrate not only 
efficacy but also cost-effectiveness. In this study, despite the higher drug costs, 
overall costs were lower in the exenatide cohorts than in the BI cohort due largely to 
fewer primary care contacts and hospital admissions. Several studies have 
investigated the cost-effectiveness of exenatide versus insulin. In a systematic 
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review and economic evaluation carried out by Waugh and colleagues, the cost- 
effectiveness of EBID versus insulin glargine was estimated as approximately £20,000 
per quality-adjusted life years (QALY), decreasing to £1,600 per QALY in patients with 
a BMI of 35kg/m2.23 Insulin dose increases with weight whereas exenatide is 
prescribed as a fixed dose and, indeed, the authors reported an improvement in the 
cost of EBID relative to insulin glargine as BMI increased.23 A further small benefit for 
EBID in terms of QALY was reported due to its association with weight loss.23 Several 
other studies have investigated the cost-effectiveness of EBID versus insulin glargine 
and EBID was shown to be cost-effective in Germany,
24
 Switzerland
25
 and the UK.
26
 
For EQW, the cost per QALY gained when compared with insulin glargine has been 
reported to be within the range that NICE normally considers as cost-effective both 
in the base-case scenario (incremental cost-effectiveness ratio, ICER,  £10,597 per 
QALY gained) and in each of the BMI subgroups investigated (BMI <30k/m2, 30–
35kg/m2 and >35kg/m2 resulted in ICERs of £9425 to £12,956 per QALY gained).27 
However, as the study was conducted prior to the launch of EQW, the price was 
derived from GLP-1 receptor agonists already on the market.27 When compared with 
insulin glargine, EQW has also been reported to cost-effective in the USA ($15,936 
per QALY) and for patients with BMI of >30kg/m
2
 in Spain (ICER €12,084 per QALY 
gained).
28
 In the CHOICE study, total healthcare costs over a 24-month period post-
initiation of the study drugs were higher in those prescribed EBID than in those 
prescribed insulin (€3997.9 versus €3265.5)
29
 when drug costs were taken into 
account but were lower for exenatide when drug costs were excluded (€1791.9 
versus €2465.5).11 However, the CHOICE study took place in several European 
countries excluding the UK and included secondary care contacts.11 In a study carried 
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out by Brice and colleagues, initiation with a GLP-1 receptor agonist was less costly 
than with a BI due to lower staff costs and fewer clinic visits (mean cost for GLP-1 
receptor agonists was £43.81 in primary care, £243.49 in intermediate care and 
£518.99 in secondary care, whereas mean cost for BI was £473.63 in intermediate 
care and £571.11 in secondary care).30 
 
Limitations 
In this study, we were able to investigate healthcare resource utilization in real-
world clinical practice. However, this study had a number of inherent limitations that 
are associated with retrospective observational studies. Patients were not 
randomized to each treatment cohort, and patient characteristics that were not 
known or could not be fully accounted for may have driven the decision to prescribe 
a particular therapy. We have aimed to reduce this risk of bias through the use of 
multivariate models and propensity-score matching. However, it is possible that 
confounding by indication and residual confounding from factors that are difficult to 
measure or quantify in retrospective data, such as diabetes severity and patient 
frailty, may exist. The purpose of the propensity matching process was to equalise 
the difference in baseline characteristics. However, it should be considered that 
those BI patients that were included in the propensity score matched cohort are 
likely to be atypical of the cohort as whole. This may affect the generalisability of the 
results.  
As with other routine data, the data sources used for this study are likely to contain 
coding imperfections, misclassifications or the omission of diagnoses. It is also likely 
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that data were not missing at random but reflected patient characteristics. 27% of 
patients had missing data for one or more of the characteristics used to generate the 
propensity score and therefore were excluded from the matching process. Missing 
data were more common in people treated with BI (32% versus 21% for EQW and 
22% for EBID). Missing data could have also affected the study outcomes. The HES 
inpatient dataset does not contain information on private treatments. As 
prescriptions are generated electronically, we expect that the completeness of the 
data was relatively high for prescriptions issued in primary care. However, 
prescriptions issued in secondary care are unlikely to be recorded in CPRD. Although 
this is difficult to quantify, we have no reason to suspect any issue of missing data in 
the recording of primary care consultations or secondary care inpatient admissions;  
should data be missing, however, this is unlikely to affect one treatment cohort 
more than another.  
Some assumptions were required when applying costs to healthcare resource use. 
Costs were only applied to consultations involving a verbal contact (face-to-face or 
via the telephone) with the patient. As discontinued medicines are no longer listed in 
the Prescription Cost Analysis for England 2014, the most recently recorded costs 
from earlier Prescription Cost Analyses were used and inflated. 
Exposure to study therapy was based on a record for one or more prescriptions in 
CPRD. However, we were not able to determine whether this prescription was then 
filled at the pharmacy or taken by the patient. Adherence to the prescribed medicine 
may have also differed between study cohorts. Misclassification of drug exposure 
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was possible. However, a consistent approach was maintained throughout the 
selection of the therapies of interest.  
Baseline characteristics were derived using data recorded prior to index date. For 
those with a short or no registration period prior to index date, we needed to rely on 
the recording of prior and current medical conditions and monitoring information at 
registration. For BMI, HbA1c, total cholesterol, blood pressure and serum creatinine, 
the nearest recorded result to index date was selected, where records were 
searched in the following order: 30 days prior to index, 30 days post-index and 365 
days prior to index date. The use of data up to 365 days prior was considered 
appropriate in order to reduce the percentage of missing data. 
 
Conclusion 
Type 2 diabetes places an increasing burden on the NHS. In this study we have 
shown that treatment with EQW and EBID was associated with reduced healthcare 
resource use and costs than BI -based regimens. Although the analysis adjusted for 
key baseline characteristics, the possibility of residual and unmeasured confounding 
should be considered when interpreting these results. 
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Tables 
Table 1 | Baseline characteristics 
a) EQW 
 Unmatched Propensity score matched 
EQW BI p-value EQW BI p-value 
N 218 8,723  188 188  
Males, N (%) 125 (57%) 4,902 (56%) 0.737 106 (56%) 102 (54%) 0.678 
Age at index, mean (SD), years 55.7 (11.3) 64.8 (15.1) <0.001 56 (11.3) 55.4 (12.7) 0.631 
Duration of diagnosed diabetes, median (IQR), years 8.0 (4.5–11.3) 9.1 (4.6–14.1) 0.005 8.0 (4.5–11.5) 7.7 (3.5–11.3) 0.207 
Smoking status, N (%)
a 
         0.730 
Non smoker 96 (44%) 3,708 (43%) 87 (46%) 80 (43%) 
Ex-smoker 90 (41%) 3,397 (39%) 74 (39%) 77 (41%) 
Current smoker 29 (13%) 1,465 (17%) 27 (14%) 31 (16%) 
BMI, mean (SD), kg/m
2b
 38 (6.5) 30 (6.4) <0.001 37.7 (5.9) 37.4 (7.9) 0.625 
HbA1c
b 
          
Mean (SD), % 9.3 (1.5) 9.7 (2) <0.001 9.3 (1.5) 9.4 (1.7) 0.676 
Mean (SD), mmol/l 77.8 (16.7) 82.3 (21.9) 78.3 (16.4) 79.1 (19) 
Concomitant glucose-lowering therapies, N (%)          <0.001 
2 oral GLTs 93 (43%) 2,222 (25%)  82 (44%) 47 (25%)  
1 oral GLT 79 (36%) 2,175 (25%)  68 (36%) 40 (21%)  
None 26 (12%) 2,156 (25%)  21 (11%) 39 (21%)  
3 oral GLTs 18 (8%) 610 (7%)  15 (8%) 17 (9%)  
4 oral GLTs 1 (0%) 13 (0%)  1 (1%) 1 (1%)  
GLP-1 receptor agonist plus other insulin 1 (0%) 4 (0%)  1 (1%) 0 (0%)  
Other insulin 0 (0%) 997 (11%)  0 (0%) 21 (11%)  
1 oral GLT plus other insulin 0 (0%) 440 (5%)  0 (0%) 15 (8%)  
2 oral GLTs plus other insulin 0 (0%) 73 (1%)  0 (0%) 6 (3%)  
3 oral GLTs plus other insulin 0 (0%) 10 (0%)  0 (0%) 0 (0%)  
1 oral GLT plus GLP-1 receptor agonist 0 (0%) 7 (0%)  0 (0%) 1 (1%)  
GLP-1 receptor agonist 0 (0%) 7 (0%)  0 (0%) 0 (0%)  
1 oral GLT plus GLP-1 receptor agonist plus other 0 (0%) 5 (0%)  0 (0%) 1 (1%)  
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insulin 
2 oral GLTs plus GLP-1 receptor agonist 0 (0%) 4 (0%) <0.001 0 (0%) 0 (0%)  
Serum creatinine, median (IQR), μmol/lb 74 (61–85) 84 (68–110) <0.001 75 (62–85.5) 71 (60–82) 0.056 
Systolic BP, mean (SD), mmHg
b 
132.6 (13.4) 132.8 (17.1) 0.838 132.8 (13.6) 134.2 (14.5) 0.331 
Diastolic BP, mean (SD), mmHg
b 
78.7 (8.9) 75.5 (10.5) <0.001 78.6 (9.2) 80.4 (9.8) 0.072 
Total cholesterol, mean (SD), mmol/l
b 
4.4 (1.1) 4.4 (1.4) 0.707 4.5 (1.1) 4.6 (1.6) 0.519 
Charlson index, median (IQR) 2 (1–3) 3 (2–5) <0.001 2 (1–3) 2 (1–3) 0.503 
GP contacts in the year prior
 
          
N (%)
a 
190 (87%) 6,032 (69%)  170 (90%) 144 (74%)  
Median (IQR) 9.5 (6–15) 12 (7–19) <0.001 9 (5–15) 10 (3.5–17) 0.013 
History of major adverse cardiac event, N (%) 20 (9%) 1,627 (19%) <0.001 16 (9%) 19 (10%) 0.594 
History of cancer, N (%) 12 (6%) 1,188 (14%) 0.001 8 (4%) 10 (5%) 0.629 
Prior prescriptions for antiplatelets, N (%) 78 (36%) 3,809 (44%) 0.02 69 (37%) 55 (29%) 0.125 
Prior prescriptions for antihypertensives, N (%) 155 (71%) 6,096 (70%) 0.699 138 (73%) 131 (70%) 0.424 
Prior prescriptions for lipid-lowering therapy, N (%) 170 (78%) 6,241 (72%) 0.037 149 (79%) 129 (69%) 0.019 
N = number of patients, SD = standard deviation, IQR = interquartile range, BMI = body mass index, GLT = glucose-lowering therapy, HbA1c = glycated haemoglobin, BP = blood pressure, 
GP = general practitioner.  
a
 Nearest status recorded prior to index date. Where no status is recorded prior to index date, nearest recorded status post-index is used.  
b
 The nearest record to the index date providing it was no more than 365 days before or 30 days after the index date. The search was conducted in the following order: −30, +30 and 
−365 days.
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b) EBID 
 Unmatched Propensity score matched 
EBID BI p-value EBID BI p-value 
N 2,180 8,723  1,486 1,486  
Males, N (%) 1,207 (55%) 4,902 (56%) 0.485 838 (56%) 841 (57%) 0.912 
Age at index, mean (SD), years 56.6 (10.5) 64.8 (15.1) <0.001 58.1 (10.2) 58.6 (12.5) 0.238 
Duration of diagnosed diabetes, median (IQR), years 7.4 (4.4–10.6) 9.1 (4.6–14.1) <0.001 7.8 (4.8–11) 7.4 (3.8–11.3) 0.018 
Smoking status, N (%)
a 
  <0.001   0.120 
Non smoker 864 (40%) 3,708 (43%) 571 (38%) 582 (39%) 
Ex-smoker 989 (45%) 3,397 (39%) 693 (47%) 647 (44%) 
Current smoker 312 (14%) 1,465 (17%) 222 (15%) 257 (17%) 
BMI, mean (SD), kg/m
2b
 38.6 (6.6) 30 (6.4) <0.001 36.9 (6) 36.1 (6.5) <0.001 
HbA1c
b 
          
Mean (SD), % 9.2 (1.6) 9.7 (2) <0.001 9.3 (1.6) 9.3 (1.8) 0.946 
Mean (SD), mmol/l 77 (18) 82.3 (21.9) 78.2 (18) 78.1 (19.3) 
Concomitant glucose-lowering therapies, N (%)          <0.001 
2 oral GLTs 955 (44%) 2,222 (25%)  683 (46%) 518 (35%)  
1 oral GLT 756 (35%) 2,175 (25%)  499 (34%) 333 (22%)  
None 275 (13%) 2,156 (25%)  161 (11%) 264 (18%)  
3 oral GLTs 185 (8%) 610 (7%)  138 (9%) 130 (9%)  
Other insulin 3 (0%) 997 (11%)  0 (0%) 117 (8%)  
1 oral GLT plus other insulin 3 (0%) 440 (5%)  2 (0%) 88 (6%)  
4 oral GLTs 3 (0%) 13 (0%)  3 (0%) 1 (0%)  
2 oral GLTs plus other insulin 0 (0%) 73 (1%)  0 (0%) 30 (2%)  
3 oral GLTs plus other insulin 0 (0%) 10 (0%)  0 (0%) 0 (0%)  
1 oral GLT plus GLP-1 receptor agonist 0 (0%) 7 (0%)  0 (0%) 1 (0%)  
GLP-1 receptor agonist 0 (0%) 7 (0%)  0 (0%) 2 (0%)  
1 oral GLT plus GLP-1 receptor agonist plus other 
insulin 0 (0%) 5 (0%)  0 (0%) 1 (0%)  
2 oral GLTs plus GLP-1 receptor agonist 0 (0%) 4 (0%)  0 (0%) 1 (0%)  
GLP-1 receptor agonist plus other insulin 0 (0%) 4 (0%) <0.001 0 (0%) 0 (0%) <0.001 
Serum creatinine, median (IQR), μmol/lb 75 (63–90) 84 (68–110) <0.001 76 (65–92) 76 (64–90) 0.280 
Systolic BP, mean (SD), mmHg
b 
134.3 (14.7) 132.8 (17.1) <0.001 134.2 (14.8) 134.6 (15.7) 0.456 
Diastolic BP, mean (SD), mmHg
b 
79.3 (9.3) 75.5 (10.5) <0.001 78.8 (9.1) 78.1 (10) 0.039 
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Total cholesterol, mean (SD), mmol/l
b 
4.3 (1.1) 4.4 (1.4) <0.001 4.3 (1.1) 4.3 (1.1) 0.658 
Charlson index, median (IQR) 2 (1–3) 3 (2–5) <0.001 2 (1–3) 2 (1–3) 0.629 
GP contacts in the year prior           
N (%) 1,916 (88%) 6,032 (69%)  1,342 (90%) 1127 (76%)  
Median (IQR) 10 (6–15.5) 12 (7–19) <0.001 10 (6–16) 12 (7–19) <0.001 
History of major adverse cardiac events, N (%) 191 (9%) 1,627 (19%) <0.001 139 (9%) 168 (11%) 0.080 
History of cancer, N (%) 127 (6%) 1,188 (14%) <0.001 99 (7%) 103 (7%) 0.771 
Prior prescriptions for antiplatelets, N (%) 996 (46%) 3,809 (44%) 0.089 705 (47%) 645 (43%) 0.027 
Prior prescriptions for antihypertensives, N (%) 1,722 (79%) 6,096 (70%) <0.001 1,180 (79%) 1,100 (74%) 0.001 
Prior prescriptions for lipid-lowering therapy, N (%) 1,847 (85%) 6,241 (72%) <0.001 1,291 (87%) 1,183 (80%) <0.001 
N = number of patients, SD = standard deviation, IQR = interquartile range, BMI = body mass index, GLT = glucose-lowering therapy, HbA1c = glycated haemoglobin, BP = blood pressure, 
GP = general practitioner.  
a
 Nearest status recorded prior to index date. Where no status is recorded prior to index date, nearest recorded status post-index is used.  
b
 The nearest record to the index date providing it was no more than 365 days before or 30 days after the index date. The search was conducted in the following order: −30, +30 and 
−365 days.
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Table 2 | Primary and secondary care contacts and costs after treatment with exenatide versus basal insulin 
a) EQW 
Healthcare resource post-index Unmatched Matched on propensity score 
  EQW BI 
Adjusted rate ratios 
(95% CI) 
EQW BI 
Adjusted rate ratios 
(95% CI)   Total Rate ppy Total 
Rate 
ppy Total Rate ppy Total Rate ppy 
Primary care contacts 
Number of contacts 5,413 29.1 230,172 35.4 0.92 (0.89–0.95) 4,665 28.5 3,893 31.8 0.89 (0.85–0.93) 
Cost of contacts, £ 181,661 976 7,664,456 1178 0.95 (0.94–0.95) 154,839 944 129,723 1,059 0.89 (0.89–0.90) 
Primary care prescriptions   
Glucose-lowering therapies, £ 170,589 914 3,309,968 507 1.55 (1.55–1.56) 152,295 926 68,410 556 1.69 (1.68–1.71) 
Other diabetes related products, £
1 
7,828 42 1,455,679 223 0.20 (0.20–0.21) 7,382 45 28,459 231 0.20 (0.19–0.20) 
All diabetes related prescriptions, £ 178,416 956 4,765,648 730 1.19 (1.19–1.20) 159,677 971 96,869 787 1.25 (1.24–1.26) 
Weight management drugs, £ 0 0 6,498 1 0 0 113 1 
Lipid-lowering therapy, £ 4,970 27 204,442 31 0.66 (0.64–0.68) 4,496 27 4,009 33 0.90 (0.86–0.94) 
Antihypertensives, £ 6,587 35 220,087 34 0.97 (0.95–1.00) 6,088 37 4,238 35 1.11 (1.06–1.15) 
Antipla elets, £ 1,560 8 47,336 7 1.46 (1.38–1.54) 1,509 9 1,964 16 1.45 (1.34–1.58) 
Secondary care admissions   
Number of admissions 109 0.6 8,466 1.3 0.69 (0.55–0.85) 84 0.5 79 0.6 0.78 (0.57–1.07) 
Number of emergency admissions 45 0.2 3,573 0.5 0.81 (0.58–1.1) 38 0.2 35 0.3 0.86 (0.54–1.40) 
Total length of stay, days 184 1.0 39,760 6.1 0.42 (0.36–0.49) 123 0.8 288 2.4 0.30 (0.24–0.37) 
Total cost of hospital admissions, £ 141,403 760 13,637,849 2,096 0.65 (0.65–0.66) 107,254 654 165,263 1,349 0.48 (0.47–0.48) 
Total 514,598 2,765 26,546,316 4,080 0.92 (0.91–0.92) 433,863 2,646 402,179 3,283 0.80 (0.80–0.81) 
ppy = per patient year 
1
 Other diabetes-related products comprised injection equipment (needles and syringes) and appliances used for the self-monitoring of blood glucose (strips and lancets)
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b) EBID 
Healthcare resource post-index Unmatched Matched on propensity score 
  EBID BI 
Adjusted rate ratios 
(95% CI) 
EBID BI 
Adjusted rate ratios 
(95% CI)   Total Rate ppy Total Rate ppy Total Rate ppy Total Rate ppy 
Primary care contacts 
Number of contacts 48,052 24 230,172 35 0.76 (0.75–0.77) 32,875 24 43,209 32 0.76 (0.75–0.77) 
Cost of contacts, £ 1,591,677 787 7,664,456 1,178 0.77 (0.76–0.77) 1,079,548 779 1,405,408 1,031 0.77 (0.76–0.77) 
Primary care prescriptions     
Glucose-lowering therapies, £ 1,686,164 832 3,309,968 507 1.53 (1.53–1.53) 1,159,326 834 759,680 556 1.50 (1.49–1.50) 
Other diabetes related products, £
1 
262,124 129 1,455,679 223 0.61 (0.61–0.62) 181,052 130 285,690 209 0.63 (0.63–0.63) 
All diabetes related prescriptions, £ 1,948,288 961 4,765,648 730 1.26 (1.26–1.27) 1,340,377 964 1,045,369 764 1.26 (1.26–1.26) 
Weight management drugs, £ 12,855 6 6,498 1 3.22 (3.10–3.34) 6,446 5 2,797 2 2.34 (2.23–2.44) 
Lipid-lowering therapy, £ 65,657 32 204,442 31 0.82 (0.81–0.83) 45,034 32 52,586 39 0.86 (0.85–0.87) 
Antihypertensives, £ 78,381 39 220,087 34 1.04 (1.03–1.06) 51,525 37 47,852 35 1.12 (1.10–1.13) 
Antiplatelets, £ 10,561 5 47,336 7 0.90 (0.88–0.92) 8,190 6 9,611 7 0.90 (0.88–0.93) 
Secondary care admissions     
Number of admissions 854 0 8,466 1 0.53 (0.48–0.57) 571 0 957 1 0.60 (0.54–0.67) 
Number of emergency admissions 301 0 3,573 1 0.49 (0.42–0.56) 201 0 451 0 0.46 (0.39–0.54) 
Total length of stay, days 2,557 1 39,760 6 0.49 (0.47–0.51) 1,684 1 3,650 3 0.51 (0.48–0.54) 
Total cost of hospital admissions, £ 1,444,848 715 13,637,849 2,096 0.58 (0.58–0.59) 979,195 706 1,622,372 1,190 0.62 (0.62–0.62) 
Total 5,152,268 2,549 26,546,316 4,080 0.82 (0.82–0.82) 3,510,315 2,532 4,185,995 3,070 0.84 (0.84–0.84) 
ppy = per patient year 
1
 Other diabetes-related products comprised injection equipment (needles and syringes) and appliances used for the self-monitoring of blood glucose (strips and lancets).
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